CD56bright NK cells have been associated with clinical remission in MS [15], and MS patients responding to treatment with IFN-β showed an expansion in CD56bright NK cells and a concurrent reduction in CD4+ and CD8+ T cells [16], [17]. This evidence concerns the gene CD8A and myeloid sarcoma.